title: Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.
abstract: The objective was to analyze risk factors for veno-occlusive disease of the liver (VOD) after allogeneic bone marrow transplantation. A cohort of 1717 recipients of HLA-identical sibling transplants for leukemia between 1988 and 1990, in 200 transplant teams worldwide, was studied. Patients were scored as having VOD if liver tissue showed typical histologic features or if they had all three of the following: (1) jaundice; (2) hepatomegaly and right upper quadrant abdominal pain; and (3) ascites and/or unexplained weight gain. Patients surviving more than 7 days post-transplant without histologic or any of these clinical features of VOD were classified as not having VOD. Patient-, disease- and transplant-related characteristics of 95 patients with VOD were compared to those of 1514 without VOD. Variables correlated with an increased risk of VOD were: pretransplant conditioning with busulfan and cyclophosphamide compared to total body radiation (relative risk (RR) 2.8; P < 0.0001), pretransplant fungal infection (RR 4.1; P = 0.011), pretransplant Karnofsky performance score < 90% (RR 1.9; P = 0.012), prior liver disease (RR 1.9; P = 0.05) and age > 20 years (RR 1.8; P = 0.05). In patients receiving radiation for conditioning, intravenous immune globulin decreased VOD risk (RR 0.26; P = 0.003). This analysis identifies risk factors for VOD. The data suggest several strategies for modifying transplant regimens to reduce VOD risk and which patients might be suitable subjects for trials of strategies of VOD prevention.
authors.affiliation: Health Policy Institute, Medical College of Wisconsin 53226, USA.
authors.forename: C
authors.initials: C
authors.lastname: Rozman
authors.forename: E
authors.initials: E
authors.lastname: Carreras
authors.forename: C
authors.initials: C
authors.lastname: Qian
authors.forename: R P
authors.initials: RP
authors.lastname: Gale
authors.forename: M M
authors.initials: MM
authors.lastname: Bortin
authors.forename: P A
authors.initials: PA
authors.lastname: Rowlings
authors.forename: R C
authors.initials: RC
authors.lastname: Ash
authors.forename: R E
authors.initials: RE
authors.lastname: Champlin
authors.forename: P J
authors.initials: PJ
authors.lastname: Henslee-Downey
authors.forename: R H
authors.initials: RH
authors.lastname: Herzig
authors.forename: W
authors.initials: W
authors.lastname: Hinterberger
authors.forename: J P
authors.initials: JP
authors.lastname: Klein
authors.forename: H G
authors.initials: HG
authors.lastname: Prentice
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
authors.forename: F E
authors.initials: FE
authors.lastname: Zwaan
authors.forename: M M
authors.initials: MM
authors.lastname: Horowitz
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D006504:Hepatic Veno-Occlusive Disease / Q000209:etiology*; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors